Dimerix Ltd has released a press release.
Westar Capital Retained as Corporate Advisors
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- CMO Appointment and Clinical Trials Update
- Half Year Report and Financial Statements
- Oversubscribed Placement to Raise a Further $4.5m
- Quarterly Review and Appendix 4C
- Results of Entitlement Offer
Later from Dimerix
- Dual Phase 2 trials launched for CKD
- Further US patent allowed for DMX-200
- Ethics Approval Received Appendix 3B and S.708A Notice
- Quarterly Review & Appendix 4C
- Executive team bolstered through CEO & md appointment
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix